Phase IV / Post-Market CROs in Japan

Japan's largest independent CRO providing end-to-end pharmaceutical development services including clinical operations, data management, regulatory affairs, and post-marketing surveillance across Asia.

Japanese CRO group providing clinical development, data management, biostatistics, and regulatory affairs services across Japan, China, Korea, and Southeast Asia.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

Japanese full-service CRO with global operations providing clinical development from early phase through post-marketing with deep oncology and CNS expertise across Asia, Europe, and the US.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

Pioneer Japanese CRO founded in 1982 providing one-stop pharmaceutical development services from early-phase through post-marketing activities in Japan and Asia.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

Japanese CRO established in 1989 offering full CRO and SMO services in Japan and Vietnam through its Asia Clinical Trial Support Alliance network.